April should mark the approval of some of the biggest drugs of 2022, including Alnylam's vutrisiran, while TG will hope to be spared pain at the PI3K adcom.
Two opportunistic buys today, of Adamas and Flexion, included a contingent value rights component.
April will see the US regulator examine Pfizer’s Jak in atopic dermatitis, and experts meet to discuss accelerated approvals in oncology.
Important data releases are on the cards for Rhythm, Wave and Supernus, among others.
The FDA will have a busy November, with decisions due for Bristol, Sanofi and Y-mabs, among others.